ePrints

High-dose rapid schedule chemotherapy for disseminated neuroblastoma

Lookup NU author(s): Professor Andrew Pearson, Emeritus Professor Alan Craft, Dr Michael Reid

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

In a high-dose schedule for disseminated neuroblastoma, eight courses of chemotherapy were administered every 10 days, regardless of myelosuppression, to eradicate tumour cells rapidly and reduce emergence of drug-resistant clones. Relatively non-myelotoxic vincristine and cisplatin were alternated with high-dose cisplatin-etoposide and cyclophosphamide-etoposide. Of 12 evaluable patients, there were 1 complete (CR), 3 very good partial (VGPR), 5 partial (PR) and 3 mixed responses (MR) 100 days after starting treatment. 6 out of 9 achieved a bone marrow CR at 40 days. 9 of 11 primary tumours were completely resected, after which 4 patients had CR, 3 VGPR (bone scan alone being abnormal), 4 PR and 1 mixed response (MR). Myelotoxicity was the major adverse effect. The only death was due to fungal infection. Clinically important renal dysfunction occurred in 3 patients. 4 had convulsions and 4 temporary hypertension. This schedule produced a rapid response and its toxicity, though serious, was manageable. Further evaluation is warranted.

Publication metadata

Author(s): Pearson, A. D. J., Craft, A. W., Pinkerton, C. R., Meller, S. T., Reid, M. M.

Publication type: Article

Publication status: Published

Journal: European Journal of Cancer

Year: 1992

Volume: 28A

Issue: 10

Pages: 1654-1659

ISSN (print): 0959-8049

ISSN (electronic): 1879-0852

URL: http://dx.doi.org/10.1016/0959-8049(92)90062-7

DOI: 10.1016/0959-8049(92)90062-7

PubMed id: 1389481

Altmetrics

Share